Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 March 2024 | Story Valentino Ndaba | Photo SUPPLIED
Off-Campus Accommodation Policy
The Off-Campus Accommodation Policy prioritises quality and safety for students.

In a move to prioritise student welfare and ensure high-quality off-campus accommodation, the University of the Free State (UFS) has introduced a comprehensive Off-Campus Accommodation Policy. This policy sets out rigorous accreditation procedures and minimum requirements for private housing providers catering to UFS students.

Naledi Ntsuku, a Higher Certificate in Music Performance student residing in Victoria Kamano student accommodation near the Bloemfontein Campus, expresses her support for the initiative, stating: “Having access to safe and comfortable off-campus accommodation enhances our overall student experience and contributes positively to our academic journey.”

Quintin Koetaan, Senior Director: Housing and Residence Affairs at the UFS, adds, “This policy reinforces our commitment to providing students with conducive living environments, both on and off campus. It sets clear standards and procedures to ensure the well-being and safety of our students.”

Key highlights of the policy include:

Accreditation Process: Accreditation is granted annually, contingent upon meeting specified requirements. Providers must submit various documents, including property deeds, building plans, and tax clearance certificates.

Minimum Requirements: Providers must adhere to standards outlined in the Minimum Accreditation Requirements document, ensuring compliance with regulatory frameworks.

Transparent Procedures: The policy emphasises fairness and consistency in accreditation decisions, providing avenues for addressing appeals and complaints.

NSFAS Funding: Accredited off-campus accommodation may qualify for financial aid from NSFAS, further supporting students’ access to quality housing.

Maintenance and Student Well-being: The policy mandates compliance with relevant legislation regarding construction, repairs, and maintenance, prioritising students’ academic activities and well-being.

Disciplinary Measures: Students residing in accredited off-campus accommodation must adhere to university policies. Transgressions may lead to disciplinary action as per UFS Rules on Student Discipline.

Ensuring quality and compliance for student welfare

The UFS Off-Campus Accommodation Policy reaffirms the university’s dedication to students’ welfare beyond campus boundaries. It aims to create a conducive living and learning environment, ensuring all enrolled students have access to safe and comfortable accommodation.

The policy states: “Students living in accredited off-campus accommodation are expected to live in accordance with the values of the UFS. The UFS policies, regulations and procedures shall also apply to students who live in accredited off-campus accommodation.” This is in alignment with the university’s commitment to Vision 130 which is the strategic plan to reposition the university by its 130th anniversary in 2034, centred around values such as excellence, innovation and impact, accountability, care, social justice, and sustainability.

By adhering to these guidelines, the UFS strives to provide a supportive and enriching experience for its student community, fostering success both academically and personally.

Click to view documentClick here for more information and access to the full policy document.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept